Introduction
============

Cancer patients experience reduced quality of life in comparison with healthy subjects as the diagnosis of cancer brings acute emotional distress. This diagnosis followed by treatment, which may include extensive surgery, toxic chemotherapy, and radiation therapy, affects patients' behavior and may have an impact on patient motivation to continue treatment and to cope with their disease. Patients' reactions to such stressors depend on many factors; thus, the ability to battle with cancer, side effects of the treatment, possible complications, and cancer rehabilitation varies among patients. Many tools are used to attempt to evaluate coping with chronic diseases; however, cancer patients require a special approach.[@b1-cmar-10-4085],[@b2-cmar-10-4085]

The way people react to serious stressors plays a significant role in their quality of life. In cancer patients, adaptation to changes made by the diagnosis of cancer depends on the coping strategy they employ. Dunkel-Schetter et al[@b3-cmar-10-4085] determined five patterns of coping in cancer patients, namely, seeking and using social support; focusing on the positive; distancing; cognitive escape avoidance; and behavioral escape avoidance. Watson et al[@b4-cmar-10-4085] developed the Mental Adjustment to Cancer (MAC) that distinguished four styles of coping with neoplastic diseases, which are anxious preoccupation, fighting spirit, helplessness--hopelessness, and positive redefinition. Researchers found that coping based on avoidance strategies is associated with greater distress, poor outcomes, and reduced quality of life, whereas coping based on seeking support and focusing on the positive is associated with less pain and distress and fewer comorbid health conditions.[@b3-cmar-10-4085]

Researchers report that coping strategies evolve over the lifetime.[@b5-cmar-10-4085] They also differ among individuals and depend on factors such as age, sex, and socioeconomic status among others.[@b5-cmar-10-4085] The socioeconomic status of lung cancer patients is particularly poor, and additionally, many of them lose the ability to work due to the severity of their disease.[@b6-cmar-10-4085] A lower level of quality of life in lung cancer patients is often associated with severe symptoms of lung cancer such as fatigue, dyspnea, and poor physical functioning (PF).[@b5-cmar-10-4085]--[@b8-cmar-10-4085]

The number of cancer patients is increasing, but the reduction in mortality due to cancer is still insufficient despite high expenditure on research on new cancer therapies.[@b7-cmar-10-4085],[@b9-cmar-10-4085] We believe that shedding more light on the relationship between coping strategies and quality of life will contribute to improvements in the heath of patients with neoplastic diseases. In the current literature, coping styles in cancer patients have not been studied sufficiently, especially among those with lung cancer who may have different coping strategies due to specific stressors (eg, dyspnea) and the stigma associated with smoked tobacco. The aim of this study was to evaluate coping strategies in patients with lung cancer and to assess how coping strategies along with other factors affect their quality of life.

Patients and methods
====================

This observation-based cross-sectional study group included 185 patients with non-small-cell lung carcinoma (NSCLC), all of whom were treated in the Department of Internal Medicine at the Lower Silesian Center for Pulmonary Diseases in Wroclaw, Poland. All the patients were informed about the aim of the study; they gave their written informed consent to participate in the study and to answer the questionnaires. The data were collected 4--6 weeks since the completion of the treatment. The study was approved by the bioethics committee of the Military Medical Chamber in Warsaw (No 152/17). The STROBE guidelines were followed.

A shortened version of the MAC scale was used to evaluate strategies for coping with the disease. The scale was initially developed by Watson et al[@b4-cmar-10-4085] in 1988 as a self-rating scale to evaluate psychological adjustment to neoplastic diseases in various types and stages of cancers. It comprised 40 questions, but it was found to have low reliability in one of the strategies (denial); therefore, the new shortened version was developed.[@b10-cmar-10-4085] The shortened version of the MAC (Mini-MAC) scale includes 29 Likert-type items rated on a 4-point scale that evaluates the following four types of strategies for coping with cancer: Anxious preoccupation translates into anxiety that patients are not able to control. The diagnosis itself as well as the deterioration in health status reflects the level of anxiety.Fighting spirit drives positive activities leading to regaining a good state of health. This strategy motivates patients to perceive the disease as a challenge.Helplessness--hopelessness translates into a perceived sense of helplessness, being lost, and giving into the disease. It is associated with a withdrawal from social and professional life.Positive redefinition allows patients to re-evaluate their current health problems, find hope, and enjoy their life despite being aware of suffering from a serious disease.

Each domain is scored separately with the total score from 7 to 28. Higher scores represent a stronger identification with a given strategy. Additionally, the presence of correlation patterns among MiniMAC domains allows the identification of the following two styles of coping with a disease: constructive (fighting spirit and positive redefinition) anddestructive (helplessness--hopelessness and anxious preoccupation).

In this study, the Polish version of the MiniMAC questionnaire was used.[@b11-cmar-10-4085],[@b12-cmar-10-4085] The reliability of the MiniMAC in Polish cancer patients is high. In the Polish population of cancer patients, the standardized Cronbach's α coefficients for the four domains are 0.88, 0.90, 0.92, and 0.87, respectively.[@b11-cmar-10-4085]

Health-related quality of life was assessed using the Short Form-8 (SF-8) Health Survey. It is the most recent version of the health survey. This scale consists of eight subscales, each with an ordinal response format, and it generates two summary measures: a physical component summary (PCS) and a mental component summary (MCS). The subscales of SF-8 are as follows: PF, role limitations due to physical health problems (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Each domain is scored from 0 to 100. Higher scores of PCS and MCS indicate a better quality of life as do all the items in the SF-8. A score of 50 is the average score in the general US population.[@b13-cmar-10-4085] In a Spanish population-based study, the SF-8 displayed very good reliability, with the Cronbach's α coefficient of 0.92 and high item-total correlations from 0.57 to 0.93.[@b14-cmar-10-4085] In another study on the Chinese population, the overall Cronbach's α was 0.85 for the eight items and the item-total correlations were moderate or high (*r* \> 0.5) for all the items, except for VT (*r*=0.39).[@b15-cmar-10-4085]

Statistical analysis
--------------------

The results from the questionnaires were collected in an Excel spreadsheet and statistically analyzed. Variables were presented as mean (SD) and numbers (percentage). The normality of distribution was checked with the Shapiro--Wilk test, which revealed that none of the analyzed variables had a normal distribution. For the comparison of more than two groups, the Kruskal--Wallis test with the Duncan's test for post hoc comparisons was used. To determine predictive values of the variables that affect quality of life, linear regression analysis was carried out. The criteria for statistical significance were set at *P*\<0.05. For the purpose of the statistical analysis, the R Package for Statistical Computing v. 3.4.4 was used.

Results
=======

In this study, 185 patients were diagnosed with NSCLC. Only the groups of NSCLC were analyzed. The mean age of patients was 62.84±9.6 with an age range between 58 and 68 years. Overall, 45.41% (n=84) were women, 41.08% (n=76) lived alone, 56.76% (n=105) had primary or vocational education, and 75.13% (n=139) were malnourished or at risk of malnutrition. The characteristics of the study group are presented in [Table 1](#t1-cmar-10-4085){ref-type="table"}.

The results of the quality of life assessment and of the evaluation of coping strategies are presented in [Table 2](#t2-cmar-10-4085){ref-type="table"}. In the scope of quality of life, the study patients achieved higher scores in the BP, RE, and VT domains, whereas poor scores in the PCS, PF, and GH domains. Mental functioning was better than PF. Regarding coping strategies, respondents most often employed the fighting strategy, whereas the sense of helplessness was employed least often. The styles of coping were assessed using standard ten norms (1--4 were classified as low; 5--6 as medium; and 7--10 as high). Overall, 65% of the respondents displayed a medium level of constructive style, whereas 62% had a destructive style. The coping style of nearly 50% of the respondents was predominantly constructive. Characteristics of the coping style in the study groups are presented in [Table 3](#t3-cmar-10-4085){ref-type="table"}.

A comparison of the quality of life scores between patients with different coping styles revealed that significant differences were found within every domain of quality of life. Overall, patients with a predominance of the constructive style had a significantly higher level of quality of life than patients with both a predominance of the destructive style and a balance between the two styles. The two exceptions were the domains of GH and MH. In the GH domain, the highest level of quality of life was observed among patients with a predominantly constructive style, a medium level of quality of life for patients with a balance between the two styles, and the lowest quality of life among those with a predominantly destructive style of coping. In the MH domain, the highest level of quality of life was observed among patients with a predominantly constructive style, whereas the remaining styles had a comparably lower quality of life. [Table 4](#t4-cmar-10-4085){ref-type="table"} shows the comparison of coping styles within the domains of quality of life.

Other factors that were analyzed affected quality of life as well. A higher score in both PCS and MCS was inversely correlated with the number of symptoms (*r*=−0.226; *P*=0.002 and *r*=−0.148; *P*=0.044). The highest PCS scores were found in patients with WHO grade 0 in comparison to other grades (the mean scores in WHO grades 0, 1, and 2--3 were 55.33, 45.47, and 26.58, respectively; *P*\<0.001); in patients without comorbidities in comparison to those with comorbidities (the mean scores in patients without comorbidities, with 1, and with 2--3 comorbidities were 52.42, 36.66, and 28.05, respectively; *P*\<0.001); in patients who were not subjected to a given type of treatment in comparison with those who were undergoing this type of treatment: radiotherapy (the mean scores for non-radiotherapy and radiotherapy groups were 43.7 and 31.36, respectively; *P*=0.007), chemotherapy (the mean scores for non-chemotherapy and chemotherapy groups were 49.25 and 32.54, respectively; *P*\<0.001), and symptomatic treatment (the mean scores for non-symptomatic and symptomatic treatment groups were 41.38 and 25.78, respectively; *P*=0.046). The highest MCS score was found in patients with WHO grade 0 in comparison to other grades (the mean scores in WHO grades 0, 1, and 2--3 were 61.76, 55.31, and 38.91, respectively; *P*=0.004); in patients without comorbidities in comparison to those with comorbidities (mean scores in patients without comorbidities, with 1, and with 2--3 comorbidities were 63.91, 47.56, and 34.76, respectively; *P*\<0.001); in patients who were not subjected to surgery (the mean scores for non-surgery and surgery groups were 37.26 and 55.4, respectively; *P*=0.002), radiotherapy (the mean scores for non-radiotherapy and radiotherapy groups were 54.62 and 39.77, respectively; *P*=0.027), chemotherapy (the mean scores for non-chemotherapy and chemotherapy groups were 65.06 and 38.11, respectively; *P*\<0.001), and symptomatic treatment (the mean scores for non-symptomatic and symptomatic treatment groups were 52 and 31.25, respectively; *P*=0.025). Patients with T1 had a higher MCS score than patients with T4 (the mean score was 61.89 vs 38.64, respectively; *P*=0.022). Also, the better nourished the patients, the better quality of life they had (*P*\<0.001 both for PCS and MCS). The comparison of coping styles within domains of quality of life is shown in [Table 4](#t4-cmar-10-4085){ref-type="table"}.

Multivariate linear regression showed that after adjusting for other factors analyzed in the study, employing a constructive style of coping with the disease increases PCS by 12.83 points and MCS by 22.21 points on average. Among other significant positive predictors of quality of life were a lower WHO grade, symptomatic treatment, better nutritional status, and a higher level of education. The results of linear regression are presented in [Table 5](#t5-cmar-10-4085){ref-type="table"}.

Discussion
==========

The results of this study provide important insights into coping strategies employed by patients with lung cancer. In this study group, a fighting strategy was most frequently observed, whereas a sense of helplessness was employed least often. Patients with a predominance of the constructive style of coping had a significantly higher level of quality of life. Regarding quality of life, the patients in the study achieved higher scores in the domains of BP, RE, and VT, whereas poor scores in the domains of PCS, PF, and GH. Patients achieved higher score in MCS than in PCS. Apart from the type of coping strategy, quality of life was associated with the patients' general state of health and the progression of the disease, which translated into a negative correlation between quality of life and the number of symptoms and comorbidities, the WHO grade, malnutrition, and being subjected to treatments such as surgery, radiotherapy, chemotherapy, and symptomatic treatment. The limitations of this study include the potential bias arising from the use of self-reported questionnaires; however, this is the nature of short form questionnaires. There was no control group in this study and as a result, we were able to identify a correlation between quality of life and coping with the disease only among lung cancer patients.

The relationship between quality of life and coping strategy is complex and additionally may be affected by many other factors. Studies from the literature suggest a reduced quality of life in patients with lung cancer. Lee et al[@b16-cmar-10-4085] reported that quality of life in NSCLC patients was lower in comparison to healthy controls, especially when measured up to 1 year after diagnosis. A comparison of health-related quality of life among cancer survivors performed by So et al[@b17-cmar-10-4085] suggested that lung cancer patients may experience a lower level of quality of life than patients with other types of cancers, especially in the area of functional well-being. Liao et al[@b18-cmar-10-4085] examined a group of patients with newly diagnosed stage IIIB or stage IV lung cancer and revealed that they had a compromised global quality of life and relatively low social and role functioning at 3 months after the diagnosis of cancer. Wang and Fu[@b19-cmar-10-4085] evaluated quality of life in Chinese patients with lung cancer and found that quality of life scores were lowest on the functioning subscale, whereas they were highest on the family subscale. The most frequent severe symptoms reported by those patients were fatigue, dry mouth, and shortness of breath. Those findings are in line with the results of this study, as quality of life in patients from this study group had low scores in the domains of GH and PCS, which are the most likely to be affected by the severity of pulmonary symptoms. It is worth noting that a cross-sectional survey completed by 660 lung cancer patients showed that quality of life was ranked the first and most important factor out of other factors experienced by those patients.[@b20-cmar-10-4085]

Only a few studies have addressed coping strategies in patients with neoplastic diseases, despite the fact that coping is considered one of the key components of health and overall quality of life as the coping strategy used by patients affects their emotions and motivation during the stressful period of the illness. Tuncay[@b21-cmar-10-4085] examined the influence of coping on quality of life among 228 patients with ovarian cancer. He found that more patients employed problem-focused coping strategies, such as acceptance, emotional support, and religion, than emotion-focused coping strategies, such as self-distraction, venting, and behavioral disengagement. Additionally, more problem-focused and less emotion-focused coping predicted a higher level of quality of life. Kershaw et al[@b22-cmar-10-4085] found that active coping was correlated with higher level of quality of life, whereas avoidant coping was correlated with a lower level of quality of life in patients with advanced breast cancer. Horney et al[@b23-cmar-10-4085] revealed the occurrence of the association between negative coping styles and a high anxiety level as well as between a low level of optimism and a higher level of depression in 103 patients just after being given a diagnosis of head and neck cancer. Our findings are similar and show that a constructive style of coping is associated with a higher quality of life.

Regarding lung cancer, we found only a few studies addressing coping strategies. Mosher et al[@b24-cmar-10-4085] focused on identifying strategies of coping with physical and psychological symptoms of advanced lung cancer although they did not study their influence on quality of life. They found that in a group of 38 patients, religious and cognitive coping strategies such as changing expectations, maintaining positivity, and avoiding illness-related thoughts were the most frequently reported. A group of 243 patients with lung cancer undergoing chemotherapy in outpatient settings from a study by Czerw et al[@b25-cmar-10-4085] predominantly employed the fighting spirit strategy of coping. Rolke et al[@b26-cmar-10-4085] reported significantly reduced coping abilities as measured by the Sense of Coherence questionnaire in depressed patients with primary lung cancer in comparison to nondepressed ones, but no association was found between the ability to cope and the total score for quality of life. Interestingly, a significant association appeared between coping abilities and the emotional functioning domain of quality of life. In the study performed by Liao et al,[@b18-cmar-10-4085] self-efficacy for coping with cancer was the most important predictive factor for quality of life in patients with newly diagnosed advanced lung cancer.

This study brings new insights into the status of coping strategies among lung cancer patients. We found that the majority of patients employed positive fighting strategies for coping, which is in line with the previously published papers. We also found a strong association between the type of coping and the level of quality of life, despite the fact that quality of life is a complex condition and it is influenced by many other factors. This study highlights the need to evaluate types of coping strategies and quality of life in patients with lung cancer. Patient-oriented outcomes are important for treatment and prognosis; although, they are rarely screened in clinical practice. This type of support requires further research. We believe that this study will help physicians to support patients in using the most effective coping strategies.

Conclusion
==========

The majority of patients with lung cancer use effective strategies for coping with the disease based on the constructive style. Patients who used a predominantly constructive style had a significantly higher level of quality of life, which may translate into better outcomes. Physicians should support patients in coping with lung cancer and provide interventions that promote positive, constructive, problem-oriented strategies, especially in patients with a lower level of quality of life, a more advanced disease, and comorbidities.

This study was performed within project number ST.E020.17.050 of Wroclaw Medical University.
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###### 

Characteristics of the study group of patients with non-small-cell lung carcinoma (n=185)

  Variables                                                  n       Percentage
  -------------------------------------- ------------------- ------- ------------
  Classification of malignant tumors T   T1                  41      22.17
  T2                                     76                  41.09   
  T3                                     21                  11.35   
  T4                                     44                  23.78   
  Tx                                     2                   1.08    
  Missing data                           1                   0.54    
  Classification of malignant tumors N   N0                  68      36.76
  N1                                     42                  22.70   
  N2, N3                                 63                  34.06   
  Nx                                     11                  5.95    
  Missing data                           1                   0.54    
  Classification of malignant tumors M   M0                  128     69.19
  M1                                     38                  20.54   
  Mx                                     18                  9.73    
  Missing data                           1                   0.54    
  TNM                                    I                   68      36.76
  II                                     42                  22.70   
  III                                    18                  9.73    
  IV                                     57                  30.81   
  The presence of comorbidities          Diabetes mellitus   54      29.19
  Ischemic heart disease                 28                  15.14   
  Renal insufficiency                    6                   3.24    
  Rheumatoid arthritis                   4                   2.16    
  Heat failure                           36                  19.46   
  Asthma/COPD                            38                  20.54   
  The presence of metastases             Bone metastases     10      5.41
  Brain metastases                       8                   4.32    
  Hepatic metastases                     17                  9.19    
  Metastases to the                      20                  10.81   
  adrenal glands                                                     
  Multi-organ metastases                 16                  8.65    
  Treatment                              Surgery             132     71.35
  Radiotherapy                           55                  29.73   
  Chemotherapy                           102                 55.14   
  Symptomatic treatment                  16                  8.65    
  Alternative treatment                  3                   1.62    
  The presence of symptoms               Chronic cough       149     80.54
  Dyspnea                                114                 61.62   
  Chest pain                             74                  40.00   
  Hemoptysis                             57                  30.81   
  Recurrent infections                   52                  28.11   
  Superior vena cava                     4                   2.16    
  syndrome                                                           
  Heart arrhythmia                       7                   3.78    
  Hoarseness                             52                  28.11   
  Mini-nutritional assessment            Malnourished        95      51.35
  At risk of malnutrition                44                  23.78   
  Normal nutritional                     46                  24.86   
  status                                                             
  WHO performance status                 Grade 0             34      18.38
  Grade 1                                80                  43.24   
  Grade 2                                61                  32.97   
  Grade 3                                9                   4.86    
  Grade 4                                1                   0.54    

###### 

Characteristics of quality of life as measured using the SF-8 questionnaire and coping with the disease as measured using the MiniMAC scale

  Variables                                         n     Mean    SD      Median   Min   Max     Q1      Q3
  ------------------------------------------------- ----- ------- ------- -------- ----- ------- ------- -------
  Quality of life domains (SF-8)                                                                         
  GH                                                185   28.65   22.2    25       0     75      0       50
  VT                                                185   52.16   36.43   50       0     100     50      100
  PF                                                185   31.89   36.25   0        0     100     0       50
  RP                                                185   42.7    49.6    0        0     100     0       100
  SF                                                185   45.41   49.92   0        0     100     0       100
  MH                                                185   47.03   50.05   0        0     100     0       100
  RE                                                185   56.22   49.75   100      0     100     0       100
  BP                                                185   56.89   38.08   75       0     100     0       100
  PCS                                               185   40.07   28.58   37.5     0     93.75   18.75   68.75
  MCS                                               185   50.2    39.26   37.5     0     100     12.5    87.5
  Strategies of coping with the disease (MiniMAC)                                                        
  Anxious preoccupation                             185   19.64   4.86    20       7     28      16      23
  Fighting spirit                                   185   20.24   3.09    20       10    28      18      22
  Helplessness--hopelessness                        185   14.92   3.58    15       7     25      13      17
  Positive redefinition                             185   20.1    2.89    20       11    28      18      22

**Note:** RE, role limitations due to emotional problems; RP, role limitations due to physical health problems.

**Abbreviations:** BP, bodily pain; GH, general health perceptions; max, maximum; MCS, mental component summary; MH, mental health; min, minimum; PCS, physical component summary; PF, physical functioning; SF, social functioning; SF-8, Short Form-8; VT, vitality.

###### 

Styles of coping with the disease among lung cancer patients

  Style                                Level       n       Percentage
  ------------------------------------ ----------- ------- ------------
  Constructive                         Low level   26      14.05
  Medium level                         120         64.86   
  High level                           39          21.08   
  Destructive                          Low level   50      27.03
  Medium level                         115         62.16   
  High level                           20          10.81   
  Predominance of destructive style    --          41      22.16
  Balance between styles               --          56      30.27
  Predominance of constructive style   --          88      47.57

###### 

Comparison of coping styles within domains of quality of life

  SF-8   Predominance of coping style   N             Mean±SD       Median     Range         IQR       P
  ------ ------------------------------ ------------- ------------- ---------- ------------- --------- ---------
  GH     D                              41            14.63±15.79   25         0--50         0--25     \<0.001
  B      56                             25±21.32      25            0--75      0--50         C\>B\>D   
  C      88                             37.5±21.44    50            0--75      25--50                  
  VT     D                              41            31.71±31.14   50         0--100        0--50     \<0.001
  B      56                             44.64±33.95   50            0--100     0--50         C\>B,D    
  C      88                             66.48±34.51   50            0--100     50--100                 
  PF     D                              41            13.41±31.67   0          0--100        0--0      \<0.001
  B      56                             24.11±30.14   0             0--100     0--50         C\>B,D    
  C      88                             45.45±36.86   50            0--100     0--50                   
  RP     D                              41            19.51±40.12   0          0--100        0--0      \<0.001
  B      56                             37.5±48.85    0             0--100     0--100        C\>B,D    
  C      88                             56.82±49.82   100           0--100     0--100                  
  SF     D                              41            26.83±44.86   0          0--100        0--100    0.001
  B      56                             37.5±48.85    0             0--100     0--100        C\>B,D    
  C      88                             59.09±49.45   100           0--100     0--100                  
  MH     D                              41            26.83±44.86   0          0--100        0--100    0.002
  B      56                             42.86±49.94   0             0--100     0--100        C\>D      
  C      88                             59.09±49.45   100           0--100     0--100                  
  RE     D                              41            31.71±47.11   0          0--100        0--100    \<0.001
  B      56                             51.79±50.42   100           0--100     0--100        C\>B,D    
  C      88                             70.45±45.89   100           0--100     0--100                  
  BP     D                              41            43.29±39.54   50         0--100        0--75     \<0.001
  B      56                             46.88±37.86   50            0--100     0--75         C\>B,D    
  C      88                             69.6±33.57    75            0--100     50--100                 
  PCS    D                              41            22.71±22.52   18.75      0--87.5       0--25     \<0.001
  B      56                             33.37±24.95   31.25         0--93.75   12.5--56.25   C\>B,D    
  C      88                             52.41±27.85   56.25         0--93.75   29.69--75               
  MCS    D                              41            29.27±34.64   12.5       0--100        0--62.5   \<0.001
  B      56                             44.23±8.36    37.5          0--100     12.5--87.5    C\>B,D    
  C      88                             63.78±36.9    75            0--100     34.38--100              

**Notes:** B, balance between constructive and destructive style of coping with the disease; C, predominance of constructive style; D, predominance of destructive style; RE, role limitations due to emotional problems; RP, role limitations due to physical health problems.

**Abbreviations:** BP, bodily pain; GH, general health perceptions; IQR, interquartile range; MH, mental health; MCS, mental component summary; PCS, physical component summary; PF, physical functioning; SF, social functioning; SF-8, Short Form-8; VT, vitality.

###### 

Results of multivariate linear regression

                                                              Physical component summary   Mental component summary                                             
  ----------------------------------------- ----------------- ---------------------------- -------------------------- --------- --------------- --------------- -------
  FEV1                                                        1.234                        −4.56--7.03                0.674     1.842           −7.79--11.48    0.706
  FVC                                                         −2.143                       −6.75--2.46                0.359     −2.611          −10.27--5.048   0.501
  FEV1/FVC \[%\]                                              −0.013                       −0.25--0.22                0.913     0.189           −0.2--0.58      0.342
  Number of symptoms                                          0.179                        −2.09--2.45                0.876     1.7             −2.07--5.47     0.374
  Sex                                       Women             Reference                                                         Reference                       
  Men                                       0.275             −5.77--6.32                  0.929                      2.787     −7.27--12.85    0.585           
  Age                                       ≤60 years         Reference                                                         Reference                       
  \>60 years                                --2.125           −8.41--4.16                  0.505                      −0.887    −11.35--9.57    0.867           
  Marital status                            In relationship   Reference                                                         Reference                       
  Alone                                     1.538             −4.86--7.94                  0.636                      6.737     −3.91--17.38    0.213           
  Education                                 Primary           Reference                                                         Reference                       
  Vocational                                −0.178            −10.9--10.5                  0.974                      −8.6      −26.37--9.17    0.34            
  Secondary                                 −1.293            −12.8--10.21                 0.824                      −17.609   −36.73--1.52    0.071           
  Higher                                    −6.684            −21.01--7.64                 0.358                      −33.714   −57.54 to       0.006           
                                                                                                                                −9.89                           
  WHO grade                                 0                 Reference                                                         Reference                       
  1                                         −7.687            −15.72--0.347                0.061                      −6.988    −20.35--6.37    0.303           
  2--4                                      −16.814           −25.60 to                    \<0.001                    −10.206   −24.82--4.41    0.17            
                                                              −8.03                                                                                             
  Classification of malignant tumors -- T   T1                Reference                                                         Reference                       
  T2                                        −0.909            −8.36--6.55                  0.81                       −3.281    −15.68--9.12    0.602           
  T3                                        0.127             −11.04--11.29                0.982                      −9.576    −28.15--8.99    0.31            
  T4                                        6.869             −3.54--17.28                 0.194                      −7.762    −25.08--9.55    0.377           
  Classification of malignant tumors -- N   N0                Reference                                                         Reference                       
  N1                                        −2.508            −10.46--5.47                 0.535                      −4.723    −17.99--8.54    0.483           
  N2--3                                     −0.924            −8.82--6.97                  0.817                      6.848     −6.28--19.97    0.304           
  Nx                                        −10.285           −24.66--4.09                 0.159                      −10.9     −34.8--13.01    0.369           
  Classification of malignant tumors -- M   M0                Reference                                                         Reference                       
  M1                                        1.968             −6.37--10.30                 0.641                      9.699     −4.16--23.56    0.169           
  Mx                                        −7.127            −17.65--3.4                  0.183                      −4.558    −22.07--12.95   0.608           
  Comorbidities                             None              Reference                                                         Reference                       
  1                                         −6.389            −13.47--0.69                 0.077                      0.671     −11.11--12.45   0.91            
  2--3                                      −4.435            −13.34--4.46                 0.326                      −2.387    −17.19--12.41   0.75            
  Metastases                                No                Reference                                                         Reference                       
  Yes                                       −3.39             −10.96--4.18                 0.378                      −7.537    −20.13--5.05    0.239           
  Surgery                                   No                Reference                                                         Reference       --              
  Yes                                       −0.301            −9.71--9.11                  0.95                       6.015     −9.63--21.66    0.449           
  Radiotherapy                              No                Reference                                                         Reference                       
  Yes                                       0.485             −6.88--7.85                  0.897                      −1.017    −13.26--11.23   0.87            
  Chemotherapy                              No                Reference                                                         Reference                       
  Yes                                       −2.953            −11.02--5.12                 0.471                      −4.685    −18.1--8.73     0.491           
  Symptomatic treatment                     No                Reference                                                         Reference                       
  Yes                                       11.918            0.82--23.01                  0.035                      12.984    −5.47--31.43    0.166           
  MNA                                       Malnourished      Reference                                                         Reference                       
  At risk of                                7.303             −0.34--14.95                 0.061                      12.869    0.15--25.59     0.047           
  malnutrition                                                                                                                                                  
  Normal                                    28.038            20.19--35.88                 \<0.001                    32.458    19.41--45.51    \<0.001         
  Coping style                              D                 Reference                                                         Reference                       
  B                                         1.957             −5.94--9.85                  0.625                      5.881     −7.24--19.01    0.377           
  C                                         12.826            4.99--20.66                  0.002                      22.211    9.18--35.25     0.001           

**Note:** B, balance between constructive and destructive style of coping with the disease; C, predominance of constructive style; D, predominance of destructive style.

**Abbreviation:** MNA, Mini-Nutritional Assessment.
